申请人:E.R. SQUIBB & SONS, INC.
公开号:EP0491548A2
公开(公告)日:1992-06-24
Disclosed herein is a process for preparing a monoacyl of the formula
in which the associated diacyl is hydrolyzed in the presence of one or more water-soluble enzymes or microorganisms capable of selectively hydrolyzing the -O-C-(O)-R1 group, wherein the treatment is carried out in a biphasic solvent system comprising an aqueous phase having the enzymes or microorganisms and an organic phase immiscible in water having the diester. This acyl-alcohol is oxidized to the associated acyl-aldehydes, which are hydrolyzed with an alkali metal carbonate, bicarbonate or hydroxide to the cis furanol. The thromboxane receptor antagonist [1S-[1α,2α(Z),3α,4α]]-7-[3[[[[(1-oxoheptyl)-amino]acetyl]amino]methyl-7-oxabicyclo-[2.2.1 ]-hept-2-yl]-5-heptenoic acid may be prepared using these processes.
本文公开了一种制备式如下的单酰基的工艺
其中相关的二酰基在一种或多种能够选择性水解-O-C-(O)-R1 基团的水溶性酶或微生物存在下水解,处理在双相溶剂系统中进行,该系统包括具有酶或微生物的水相和具有二酯的不溶于水的有机相。这种酰基醇被氧化成相关的酰基醛,再用碱金属碳酸盐、碳酸氢盐或氢氧化物水解成顺式呋喃醇。血栓素受体拮抗剂[1S-[1α,2α(Z),3α,4α]]-7-[3[[[[(1-氧代庚基)-氨基]乙酰基]氨基]甲基-7-氧杂双环-[2.2.1 ]-庚-2-基]-5-庚烯酸可用上述工艺制备。